Fox Run Management L.L.C. Buys 12,848 Shares of LivaNova PLC (NASDAQ:LIVN)

Fox Run Management L.L.C. grew its stake in LivaNova PLC (NASDAQ:LIVN) by 183.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 19,843 shares of the company’s stock after purchasing an additional 12,848 shares during the period. Fox Run Management L.L.C.’s holdings in LivaNova were worth $919,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the stock. Central Pacific Bank Trust Division lifted its stake in shares of LivaNova by 21.2% during the 4th quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock worth $191,000 after acquiring an additional 720 shares during the last quarter. Vestcor Inc bought a new stake in shares of LivaNova during the 4th quarter worth approximately $204,000. Captrust Financial Advisors bought a new stake in shares of LivaNova during the 3rd quarter worth approximately $217,000. Inceptionr LLC bought a new stake in shares of LivaNova during the 4th quarter worth approximately $217,000. Finally, Sanctuary Advisors LLC bought a new stake in shares of LivaNova during the 3rd quarter worth approximately $219,000. 97.64% of the stock is owned by institutional investors.

LivaNova Stock Down 2.3 %

Shares of LIVN stock opened at $39.48 on Friday. LivaNova PLC has a 1-year low of $36.85 and a 1-year high of $64.48. The stock’s fifty day moving average price is $45.31 and its 200 day moving average price is $48.74. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The company has a market cap of $2.15 billion, a price-to-earnings ratio of 94.00 and a beta of 1.10.

Analyst Ratings Changes

Several research firms have commented on LIVN. StockNews.com downgraded LivaNova from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 26th. Wolfe Research downgraded LivaNova from an “outperform” rating to a “peer perform” rating in a report on Wednesday, February 26th. Mizuho reduced their price objective on LivaNova from $70.00 to $60.00 and set an “outperform” rating on the stock in a report on Wednesday, February 26th. Barclays reduced their price objective on LivaNova from $58.00 to $56.00 and set an “equal weight” rating on the stock in a report on Friday, March 7th. Finally, The Goldman Sachs Group reduced their price objective on LivaNova from $64.00 to $55.00 and set a “buy” rating on the stock in a report on Monday, March 3rd. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $61.17.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.